NCT05924672 2026-01-14
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
Phase 2 Active not recruiting
University of California, San Francisco
Stanford University
HTA Co., Ltd.
National Cancer Institute (NCI)